Lv1
70 积分 2025-09-22 加入
Maintenance Therapy in Acute Myeloid Leukemia
23天前
已完结
Therapeutic horizon of acute myeloid leukemia: Success, optimism, and challenges
23天前
已完结
Evaluation of European LeukemiaNet 2022 risk classification in patients undergoing allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: Identification of a very poor prognosis genetic group
23天前
已完结
Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy
23天前
已完结
Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a "real world" study
23天前
已完结
Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial
24天前
已完结
Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial
25天前
已完结
Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study
1个月前
已完结
Real-World Comparative Effectiveness of Bruton Tyrosine Kinase Inhibitors in Relapsed/Refractory Mantle Cell Lymphoma
1个月前
已关闭
Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
1个月前
已完结
皖公网安备34019202002308
